[HTML][HTML] Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during BQ. 1, BQ. 1.1., and XBB. 1.5 predominant omicron variants in three US health systems …
NR Aggarwal, LE Beaty, TD Bennett… - The Lancet Regional …, 2024 - thelancet.com
Summary Background Ritonavir-boosted Nirmatrelvir (NMV-r), a protease inhibitor with in
vitro activity against SARS-CoV-2, can reduce risk of progression to severe COVID-19
among high-risk individuals infected with earlier variants, but less is known about its
effectiveness against omicron variants BQ. 1/BQ. 1.1/XBB. 1.5. We sought to evaluate
effectiveness of NMV-r in BQ. 1/BQ. 1.1/XBB. 1.5 omicron variants by comparing
hospitalisation rates to NMV-r treated patients during a previous omicron phase and to …
vitro activity against SARS-CoV-2, can reduce risk of progression to severe COVID-19
among high-risk individuals infected with earlier variants, but less is known about its
effectiveness against omicron variants BQ. 1/BQ. 1.1/XBB. 1.5. We sought to evaluate
effectiveness of NMV-r in BQ. 1/BQ. 1.1/XBB. 1.5 omicron variants by comparing
hospitalisation rates to NMV-r treated patients during a previous omicron phase and to …
Real-world use of nirmatrelvir-ritonavir in COVID-19 outpatients during the emergence of Omicron variants BA. 2/BA2. 12.1
NR Aggarwal, KC Molina, LE Beaty, TD Bennett… - Medrxiv, 2022 - medrxiv.org
ABSTRACT Background Ritonavir-boosted Nirmatrelvir (NMV-r), a protease inhibitor with in
vitro activity against SARS-CoV-2, has been shown to reduce risk of progression to severe
COVID-19 among high-risk individuals during the Delta-variant phase. We sought to
determine the effectiveness of NMV-r against Omicron lineage variants BA. 2/BA2. 12.1, and
assess for evidence of a clinical rebound effect. Methods We conducted a retrospective
observational cohort study of non-hospitalized adult patients with SARS-CoV-2 infection …
vitro activity against SARS-CoV-2, has been shown to reduce risk of progression to severe
COVID-19 among high-risk individuals during the Delta-variant phase. We sought to
determine the effectiveness of NMV-r against Omicron lineage variants BA. 2/BA2. 12.1, and
assess for evidence of a clinical rebound effect. Methods We conducted a retrospective
observational cohort study of non-hospitalized adult patients with SARS-CoV-2 infection …
以上显示的是最相近的搜索结果。 查看全部搜索结果